Petros Pharmaceuticals annual return on equity
2021
2022
2023
2024
Petros Pharmaceuticals Return on Equity (ROE) Growth & History (PTPI)
Petros Pharmaceuticals's return on equity was −622.09% for fiscal 2024.
View full Petros Pharmaceuticals company overviewPetros Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −622.09% | −565.35 pp |
| 2023 | 2023-12-31 | −56.74% | +19.96 pp |
| 2022 | 2022-12-31 | −76.70% | −42.80 pp |
| 2021 | 2021-12-31 | −33.90% | — |
Petros Pharmaceuticals quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −77.31% | — |
| Q1 2026 | 2026-03-31 | −42.52% | — |
| Q4 2025 | 2025-12-31 | −10.79% | — |
| Q3 2025 | 2025-09-30 | −23.61% | +16.09 pp |
| Q3 2024 | 2024-09-30 | −39.70% | +6.07 pp |
| Q2 2024 | 2024-06-30 | −7.41% | +10.52 pp |
| Q1 2024 | 2024-03-31 | −19.79% | −11.17 pp |
| Q4 2023 | 2023-12-31 | 3.35% | +25.92 pp |
| Q3 2023 | 2023-09-30 | −45.78% | +4.60 pp |
| Q2 2023 | 2023-06-30 | −17.94% | −12.76 pp |
| Q1 2023 | 2023-03-31 | −8.62% | −8.13 pp |
| Q4 2022 | 2022-12-31 | −22.58% | +8.09 pp |
| Q3 2022 | 2022-09-30 | −50.37% | −41.28 pp |
| Q2 2022 | 2022-06-30 | −5.18% | +5.28 pp |
| Q1 2022 | 2022-03-31 | −0.49% | −16.16 pp |
| Q4 2021 | 2021-12-31 | −30.66% | — |
| Q3 2021 | 2021-09-30 | −9.09% | — |
| Q2 2021 | 2021-06-30 | −10.46% | — |
| Q1 2021 | 2021-03-31 | 15.68% | — |
Petros Pharmaceuticals return on equity trends
Between the periods ended 2021-12-31 and 2024-12-31, Petros Pharmaceuticals's return on equity decreased from −33.90% to −622.09%, a change of −588.18 percentage points. The latest reported quarter, Q2 2026, shows −77.31%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals source filings ↗